Abstract
Background: Genome editing at specific sites in vivo is currently limited by vector capacity, the efficiency of editing proteins, and the internal physiological environment. These factors often lead to ineffective gene editing or adverse effects. Methods: We developed a single-vector recombinant adeno-associated virus (rAAV) system containing Staphylococcus aureus Cas9 (SaCas9) and guide RNAs (sgRNAs) driven by compact EF1α and tRNA promoters. This system was used to knock out the Myostatin (Mstn) gene in the thigh muscles of a mouse model of muscular atrophy. Results: The rAAV-SaCas9 system demonstrated stable, long-term expression. Increasing viral titers and reaction time improved editing efficiency and protein expression both in vitro and in vivo. Crucially, partial knockout of the Mstn gene improved muscle cell morphology and mass in the atrophy model. Conclusions: The rAAV-SaCas9 system offers a potent and streamlined approach for treating muscular atrophy through targeted gene therapy.
Introduction
Adeno-associated viruses (AAVs) are the preferred vehicle for in vivo gene delivery due to their low toxicity and high tissue specificity. However, their utility in CRISPR/Cas9 therapy is hindered by a strict packaging limit of approximately 4.85 kb. The widely used Streptococcus pyogenes Cas9 (SpCas9) is roughly 4.3 kb, leaving insufficient space for necessary regulatory elements like promoters and sgRNAs. While "split-vector" systems exist, they require a single cell to be co-infected by two separate viruses, significantly reducing efficiency. This study presents an "all-in-one" solution that fits within a single AAV vector by utilizing a smaller Cas9 ortholog and space-saving promoters.
Engineering a Compact CRISPR/Cas9 Vector
To overcome the AAV cargo limitation, the researchers implemented several strategic engineering choices. They utilized SaCas9, which is approximately 1 kb shorter than SpCas9 but maintains high editing potency. To further save space, they replaced the standard U6 promoter (~250 bp) for driving sgRNA with a much smaller tRNA promoter (~70 bp). A "subtle" version of the EF1α promoter was used to drive SaCas9 expression, and a P2A-eGFP reporter was included to allow for visual tracking of successful transduction.
Initial validation in NIH/3T3 and C2C12 muscle cells confirmed that the system could be expressed effectively. As shown in Figure 1, the compact vector design (A) successfully expressed SaCas9 (B) and achieved significant editing efficiency at the target locus (C-E).
Therapeutic Efficacy in Muscular Atrophy
The system was designed to target Myostatin (Mstn), a negative regulator of muscle growth. By inhibiting this "brake" on muscle development, the researchers aimed to counteract the effects of muscular atrophy. The study utilized a Dexamethasone (DEX)-induced mouse model to mimic clinical muscle wasting.
Key Findings:
- Editing Efficiency: The system achieved up to 24.84% editing efficiency in C2C12 cells and 21.68% in vivo at high viral doses.
- Muscle Mass Recovery: Treatment with rAAV9-SaCas9 led to a significant increase in the weight of the quadriceps and adductor muscles (P < 0.01) compared to untreated atrophy controls.
- Histological Improvement: Histological analysis revealed increased muscle fiber area and density in treated mice, indicating structural recovery of the muscle tissue.
- Protein Reduction: Western blot analysis confirmed a steady decline in Myostatin protein levels over a 10-week period following a single intramuscular injection.
Discussion and Future Directions
The use of tRNA promoters proved to be a critical innovation, providing high efficiency in muscle tissue while maintaining a minimal genetic footprint. Because Myostatin is a secreted protein, even partial editing within a muscle group can yield broader therapeutic benefits to the surrounding tissue. Deep sequencing also indicated high specificity with minimal off-target mutations, supporting the safety profile of SaCas9 for in vivo use.
While these results are promising for local treatment, future work must address systemic delivery challenges for diseases like Duchenne Muscular Dystrophy (DMD). Additionally, the long-term immunogenicity of bacterial SaCas9 in humans requires further investigation. Nonetheless, this single-vector blueprint significantly advances the feasibility of AAV-based muscle gene therapies.
Summary updated